Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Fixed-duration epcoritamab in combination with bendamustine + Rituximab (BR) for first-line (1L) treatment of follicular lymphoma (FL): 3-year results from EPCORE NHL-2 arm 3 demonstrate deep and durable responses with manageable safety

View Full Paper
Ask AI
Bookmark
Share

Authors

FOFritz OffnerPPPoliana PatahIAIşıl Altıntaş

Discussion

Loading...

Member takes

Overview

Phase 1b/2 trial reports 96% complete response and 83% progression-free survival in 1L follicular lymphoma, indicating favorable safety profile and efficacy of epcoritamab plus BR.

Key Points

  • At a median follow-up of 41.3 months, complete response rate for epcoritamab plus BR was 96%.
  • Overall survival was estimated at 96% with 3-year progression-free survival at 83%, suggesting durable responses.
  • Epcoritamab plus bendamustine and rituximab was administered for a total treatment duration of up to two years.
  • Long-term efficacy supports the use of epcoritamab as a core therapeutic option for first-line follicular lymphoma.

Cite This Study

Offner et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db50https://doi.org/10.1182/blood-2025-5357
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Epcoritamab with rituximab + lenalidomide (R2) and epcoritamab maintenance deliver deep and durable remissions in previously untreated (1L) follicular lymphoma (FL): 3-year outcomes from epcore NHL-2 arms 6 and 72025 · 1 citations
  2. 2Sustained remissions beyond 4 years with epcoritamab monotherapy: Long term follow-up results from the pivotal EPCORE NHL-1 trial in patients with relapsed or refractory large B-cell lymphoma2025
  3. 3Fixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma2025
  4. 4Fixed-duration epcoritamab + R-CHOP in patients with newly diagnosed DLBCL and high IPI scores (3–5) led to sustained remissions and disease-free survival beyond 3 years: Results from the EPCORE NHL-2 trial2025 · 4 citations
  5. 5Durable responses in patients with large B-cell lymphoma and 3+ prior lines of therapy who either paused or discontinued epcoritamab monotherapy while in complete response2025